2,8-dihydroxy-11,12-dihydro-6,13-dioxabenzo[3,4]cyclohepta[1,2-a]naphthalene-5-one | 554431-14-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 2,8-dihydroxy-11,12-dihydro-6,13-dioxabenzo[3,4]cyclohepta[1,2-a]naphthalene-5-one
• 英文别名: 2,8-dihydroxy-11,12-dihydro-6,13-dioxa-benzo[3,4]cyclohepta[1,2-a]naphthalen-5-one；5,15-Dihydroxy-8,18-dioxatetracyclo[9.8.0.02,7.012,17]nonadeca-1(11),2(7),3,5,12(17),13,15-heptaen-19-one
• CAS: 554431-14-0
• 化学式: C₁₇H₁₂O₅
• 分子量: 296.279
• InChiKey: PIMKUNSPQPDNTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,8-dihydroxy-11,12-dihydro-6,13-dioxabenzo[3,4]cyclohepta[1,2-a]naphthalene-5-one 在 正丁基锂 、 二异丁基氢化铝 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 27.08h， 生成 1-Benzoxepin-5-methanol, 8-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-hydroxyphenyl]-2,3-dihydro-α-[4-[2-(1-piperidinyl)ethoxy]phenyl]-
  参考文献：
  名称：

  四环杂化合物的合成作为选择性雌激素受体调节剂。第2部分。放大2,5,8取代的11,12- Dihydro- 5 H -6,13-​​dioxabenzo [3,4]环庚-[1,2- a ]萘衍生物的工艺改进

  摘要：

  一种改进的，可重现的非色谱方法，用于大规模合成2,5,8-取代的11,12-二氢-5 H -6,13-​​二氧杂苯并[3,4]环庚[1,2- a ]萘衍生物描述了雌激素受体调节剂（SERM）。经过九个连续的合成步骤，以9-21％的总收率制备了标题化合物，具有较高的化学纯度（> 97％）。

  DOI：

  10.1021/op700061x
• 作为产物：
  描述：

  2,4-二甲氧基苯乙酸 在 乙醇 、 偶氮二甲酸二异丙酯 、 乙酸酐 、 三溴化硼 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 邻二甲苯 为溶剂， 反应 97.5h， 生成 2,8-dihydroxy-11,12-dihydro-6,13-dioxabenzo[3,4]cyclohepta[1,2-a]naphthalene-5-one
  参考文献：
  名称：

  四环杂化合物的合成作为选择性雌激素受体调节剂。第2部分。放大2,5,8取代的11,12- Dihydro- 5 H -6,13-​​dioxabenzo [3,4]环庚-[1,2- a ]萘衍生物的工艺改进

  摘要：

  一种改进的，可重现的非色谱方法，用于大规模合成2,5,8-取代的11,12-二氢-5 H -6,13-​​二氧杂苯并[3,4]环庚[1,2- a ]萘衍生物描述了雌激素受体调节剂（SERM）。经过九个连续的合成步骤，以9-21％的总收率制备了标题化合物，具有较高的化学纯度（> 97％）。

  DOI：

  10.1021/op700061x

文献信息

• Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
  申请人：——

  公开号：US20040259915A1

  公开（公告）日：2004-12-23

  The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及新颖的含杂原子四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用，以及它们的制备方法。本发明的化合物在治疗和/或预防与雌激素耗竭相关的疾病中具有用途，例如热潮红、阴道干燥、骨量减少和骨质疏松症；激素敏感性癌症以及乳腺、子宫内膜、宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎，以及作为避孕剂，单独使用或与孕激素或孕激素拮抗剂联合使用。
• Synthesis of novel tetracyclic chromenes through carbanion chemistry of 4-methyl coumarins
  作者：Ningyi Chen、Nareshkumar Jain、Jiayi Xu、Michael Reuman、Xun Li、Ronald K. Russell、Zhihua Sui

  DOI：10.1016/j.tetlet.2006.06.047

  日期：2006.8

  coumarins through lithiation, followed by reactions with a wide range of electrophiles. The presence of an alkoxy group on 6′-phenyl ring was found to be pivotal for the success of this reaction. This procedure provided a convenient synthetic pathway to elaborate the methyl group of 4-methylcoumarins. Application of this methodology was showcased with the synthesis of biologically important novel tetracyclic

  通过锂化将各种取代基引入4-甲基香豆素的甲基上，然后与各种亲电子试剂反应。发现6'-苯环上烷氧基的存在对于该反应的成功至关重要。该方法提供了合成4-甲基香豆素甲基的方便的合成途径。这种方法的应用在生物学上具有重要意义的新型四环色烯环系统的合成中得到了展示（n  = 1-3）。
• [EN] TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS<br/>[FR] HETERO-COMPOSES TETRACYCLIQUES UTILISABLES COMME MODULATEURS DU RECEPTEUR DES OESTROGENES
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2003053977A1

  公开（公告）日：2003-07-03

  The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and / or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and / or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及新型含杂原子的四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的使用以及它们的制备过程。该发明的化合物在治疗和/或预防与雌激素缺乏有关的疾病方面具有用处，例如潮热、阴道干燥、骨质疏松症和骨质疏松症；激素敏感性癌症和乳腺、子宫内膜、子宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎以及作为避孕药物，单独使用或与孕激素或孕激素拮抗剂组合使用。
• Identification and Structure−Activity Relationships of Chromene-Derived Selective Estrogen Receptor Modulators for Treatment of Postmenopausal Symptoms
  作者：Nareshkumar Jain、Jiayi Xu、Ramesh M. Kanojia、Fuyong Du、Guo Jian-Zhong、Emmanuel Pacia、Muh-Tsann Lai、Amy Musto、George Allan、Michael Reuman、Xun Li、DoWon Hahn、Martin Cousineau、Sean Peng、David Ritchie、Ronald Russell、Scott Lundeen、Zhihua Sui

  DOI：10.1021/jm900146e

  日期：2009.12.10

  As part of it program aimed at the development of selective estrogen receptor modulators (SERMs), novel chromene scaffolds, benzopyranobenzoxapanes, were discovered. Many compounds showed binding affinity as low as 1.6-200 nM, displayed antagonist behaviors in the MCF-7 human breast adenocarcinoma cell line its well in Ishikawa cell line with IC50 values in the range 0.2-360 nM. On the basis of the side chain substitution, various compounds demonstrated strong inhibitory activity in anti-uterotropic assay. Compound 7-(R) and its major metabolites 5-(R) and 6-(R) were evaluated in several in vivo models of estrogen action. Relative to a full estrogen agonist (ethynyl estradiol) and file SERM raloxifene, 7-(R) wits found to be it potent SERM that behaved its antagonist in the uterus and exhibited estrogen agonistic activity on bone, plasma lipids, hot flush, and vagina. The overall pharmacokinetic profile and stability were Significantly improved compared to those of the phase 2 development compound 9-(R).
• TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1467998A1

  公开（公告）日：2004-10-20